ReviewThe Journal of clinical and aesthetic dermatology2014
Diagnostic and prognostic biomarkers in melanoma.
Review in The Journal of clinical and aesthetic dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Systematic review: fluid biomarkers and machine learning methods to improve the diagnosis from mild cognitive impairment to Alzheimer's disease.Alzheimer's research & therapy · 2023Pooled it
- PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.Scientific reports · 2021Trial
- Therapeutic Resistance in Melanoma: Molecular Mechanisms and Emerging Pharmaceutical Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Quantifying the Interplay Between PRAME Expression and Classical Morphology: A Multivariable Analysis of 954 Suspected Melanocytic Lesions.Dermatopathology (Basel, Switzerland) · 2026Article
- Review
- Investigating tumour heterogeneity in a melanoma arising in congenital melanocytic nevus using in situ spatial gene expression analysis.Journal of clinical pathology · 2026Article
- Morphological and Optical Characterization of NRAS-Mutant Melanoma Cells and Primary Melanocytes via Quantitative Phase Imaging With Digital Holographic Microscopy.Cell biochemistry and function · 2026Article
- Article
- Article
- Spatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma.bioRxiv : the preprint server for biology · 2025Article
- Article
- Article
- AnInternational journal of molecular sciences · 2025Article
- Paradigm of biomarkers in metastatic melanoma (Review).Oncology letters · 2025Review
- Electrochemical and Optical Carbon Dots and Glassy Carbon Biosensors: A Review on Their Development and Applications in Early Cancer Detection.Micromachines · 2025Review
- he Dark Corner of the Pituitary Gland: A Case Report and Literature Review of Primary MelanocytomaCurrent medical imaging · 2025Review
- Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.World journal of experimental medicine · 2024Review
- Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA.Clinical proteomics · 2024Article
- Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.JCO precision oncology · 2024Article
- Combined Anti-PD-1 and Anti-CTLA-4 Treatment in Stage IV Melanoma Patients: A Bicentric Analysis of Real-World Data and a Modern Treatment Scenario Proving Lactate Dehydrogenase's Usefulness.Diagnostics (Basel, Switzerland) · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is a lethal melanocytic neoplasm. Unfortunately, the histological diagnosis can be difficult at times. Distinguishing ambiguous melanocytic neoplasms that are benign nevi from those that represent true melanoma is important both for treatment and prognosis. Diagnostic biomarkers currently used to assist in the diagnosis of melanoma are usually specific only for melanocytic neoplasms and not necessarily for their ability to metastasize. Traditional prognostic biomarkers include depth of invasion and mitotic count. Newer diagnostic and prognostic biomarkers utilize immunohistochemical staining as well as ribonucleic acid, micro-ribonucleic acid, and deoxyribonucleic acid assays and fluorescence in situ hybridization. Improved diagnostic and prognostic biomarkers are of increasing importance in the treatment of melanoma with the development of newer and more targeted therapies. Herein, the authors review many of the common as well as newer diagnostic and prognostic biomarkers used in melanoma.
Identifiers
25013535PMC4086529W1687945972What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.